Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Intersectoral MHPSS Emergency Preparedness and Response Plan: In the Context of the Risk of War on Lebanon

 
In response to the escalating situation and war on Lebanon, the Ministry of Public Health (MoPH) has developed and is currently implementing with all stakeholders the:
“National Intersectoral MHPSS Emergency Preparedness and Response Plan: In the Context of the Risk of War on Lebanon "

Developed through a collaborative approach by the National Mental Health Programme (NMHP) with the support of the World Health Organization, UNICEF, and all MHPSS Stakeholders (please refer to the action plan for a full list), this comprehensive plan outlines a proactive approach to anticipating, mitigating, and responding to the psychosocial impacts by focusing on early intervention and support to minimize the adverse effects on individuals, healthcare personnel and communities. It underscores the commitment of the MoPH and the NMHP to safeguard mental health and respond timely and effectively to the psychosocial needs of all populations residing in Lebanon during times of crisis while promoting their resilience.

Key Features of the Plan:
  • Continuity of MHPSS Services: The plan highlights actions to ensure the continued availability and accessibility of MHPSS services across Lebanon.
  • Assurance of Psychotropic Medications: The plan emphasizes ensuring the continuous supply and access to psychotropic medications to all old and new beneficiaries.
  • Communication and Messaging: The plan prioritizes the development and dissemination of key messages and tips on topics related to mental health and well-being that would promote community resilience.
  • Training and Capacity Building: The plan places a strong emphasis on training healthcare professionals and frontline responders in MHPSS principles and practices to provide effective support to service users and providers.
The MoPH is implementing this action plan with all stakeholders, including governmental bodies, local authorities and municipalities, non-governmental organizations, healthcare providers, frontliners, and the international community - Please do reach out if your organization is interested to join in implementing this crucial plan and working together to ensure the mental health and psychosocial support of Lebanon’s residents during times of adversity.

Kindly find a selection of valuable links below:
    1
    ...
ATC Name B/G Ingredients Dosage ↓ Form Price
J07BK01 VARILRIX + SOLVENT IN SYRINGE B Varicella virus, live attenuated - ?1033 PFU ?1033 PFU Injectable lyophilised powder for solution+diluent 3,473,833 L.L
N07CA01 VASOSERC G Betahistine dihydrochloride - 8mg 8mg Tablet 1,334,884 L.L
C09CA03 VALSANET G Valsartan - 80mg 80mg Tablet, film coated 479,944 L.L
C09CA03 VALSARTAN ARROW LAB G Valsartan - 80mg 80mg Tablet, film coated, breakable 387,027 L.L
C09CA03 VIOSTAN 80 G Valsartan - 80mg 80mg Tablet, film coated 526,786 L.L
J01AA08 VULGA XR G Minocycline - 80mg 80mg Tablet, film coated 2,832,820 L.L
J05AB01 VICLORIX 800 G Aciclovir - 800mg 800mg Tablet 4,321,797 L.L
M01AB05 VOLDEN G Diclofenac sodium - 75mg/3ml 75mg/3ml Injectable solution 422,351 L.L
M01AB05 VOTREX G Diclofenac sodium - 75mg/3ml 75mg/3ml Injectable solution 345,368 L.L
N06AX16 VENLAFAXINE ARROW GENERIQUES LP G Venlafaxine - 75mg 75mg Tablet, prolonged release 1,075,074 L.L
N06AX16 VENLAFAXINE BIOGARAN LP G Venlafaxine HCl - 75mg 75mg Capsule, prolonged release 584,571 L.L
N06AX16 VENLAX XR 75 G Venlafaxine HCl - 75mg 75mg Capsule, extended release 895,895 L.L
N06AX16 VENLAX XR 75 G Venlafaxine HCl - 75mg 75mg Capsule, extended release 1,343,843 L.L
J05AH02 VIRIFLU G Oseltamivir - 75mg 75mg Capsule 1,371,615 L.L
S01LA09 VABYSMO B Faricimab - 6mg/0.05ml 6mg/0.05ml Injectable solution 54,991,170 L.L
N07XX08 VYNDAMAX B Tafamidis - 61mg 61mg Capsule 784,020,041 L.L
B05AA07 VOLUVEN B Starch poly(O-2-Hydroxyethyl) - 6% 6% Injectable solution 987,724 L.L
S01AE07 VIGAMOX G Moxifloxacin (HCl) - 5mg/ml 5mg/ml Drops solution 670,577 L.L
R03AC02 VENTOLIN B Salbutamol (sulfate) - 5mg/ml 5mg/ml Solution 403,153 L.L
G04BE08 VIVIDA 5 G Tadalafil - 5mg 5mg Tablet, film coated 2,559,700 L.L
N05AH03 VAINCOR G Olanzapine - 5mg 5mg Tablet, coated, scored 806,306 L.L
N05BA01 VALIUM B Diazepam - 5mg 5mg Tablet, scored 200,233 L.L
G04BD08 VESICARE B Solifenacin succinate - 5mg 5mg Tablet, film coated 1,619,330 L.L
J01AA08 VULGA XR G Minocycline - 55mg 55mg Tablet, film coated 1,983,512 L.L
L01EF03 VERZENIO B Abemaciclib - 50mg 50mg Tablet 76,122,299 L.L
A10BH02 VILDAVITAE G Vildagliptin - 50mg 50mg Tablet 665,202 L.L
A10BH02 VILDIAB G Vildagliptin - 50mg 50mg Tablet 806,306 L.L
A10BH02 VLUDIN G Vildagliptin - 50mg 50mg Tablet 767,910 L.L
A10BH02 VLUDIN G Vildagliptin - 50mg 50mg Tablet 767,910 L.L
J02AC03 VORICONAZOLE STRAGEN G Voriconazole - 50mg 50mg Tablet, coated 15,808,184 L.L
    1
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025